Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Evie SA is currently building a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The prosecution activity is concentrated around 1 pending office action. This single active matter indicates that the applicant is currently focused on a specific set of claims or a single application within this technical sector. Such a limited volume of activity suggests a highly specialized or early-stage filing strategy for their biological innovations.
The examination process for this portfolio is limited to 1 distinct examiner and 1 distinct art unit. This high degree of concentration suggests that the subject matter is specialized and falls under the jurisdiction of a single regulatory group at the patent office. For the practitioner, this means that the prosecution strategy is entirely contained within one technical silo, reducing the need to navigate different procedural norms across multiple art units.
CAIN, JENNIFER LYNN is the busiest examiner assigned to the portfolio, currently overseeing 1 pending office action. Because the total number of pending office actions is 1, this examiner is the sole point of contact for the company active filings. The busiest examiner pending count of 1 confirms that there is no fragmentation in the current examination workload, allowing for a direct and focused interaction with the assigned official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAIN, JENNIFER LYNN | 1 | 43.5% | +67.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638430 | LOADED GRANULES, THEIR PROCESS OF PRODUCTION AND THEIR USES | CAIN, JENNIFER LYNN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17638430 | LOADED GRANULES, THEIR PROCESS OF PRODUCTION AND THEIR USES | CAIN, JENNIFER LYNN | 1655 | §103 | Final Rejection | — | Pending | Feb 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEvie SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer Lynn Cain has the most, with 1 of Evie SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
